← boardnext 2027-06-25next 2027-07
APLS
Apellis Pharmaceuticals, Inc.distress 0/10 · well-funded / low risk$41.030%today0% from 52w high
Lead: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Revenue
$268M
Liquidity
$405M
Runway
—
Shares 1y
—
Price & events
+86.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.5%
1M
+89.1%
3M
+101.8%
6M
+150.8%
1Y
—
2Y
—
5Y
+23.7%
All
Overview
- Volume
- 0
- 52 Week Range
- $16.36 – $41.12
- Float Shares
- 83.22M
- Short %
- 12.55%
- % Held by Insiders
- 11.36%
- % Held by Institutions
- 110.43%
- Beta
- -0.25
Pipeline stages · 2 programs
APL-3007, pegcetacoplan (APL-2)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pegcetacoplan
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06-25 Estimated 50% readout ~2027-08-09 | Phase 2 | APL-3007, pegcetacoplan (APL-2) | Geographic Atrophy Secondary to Age-related Macular Degeneration | — | recruiting |
| 2027-07 Estimated 50% readout ~2027-09-14 | Phase 3 | Pegcetacoplan | C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | — | active not recruiting |
| 2028-12 Estimated 50% readout ~2029-01-15 | Phase 2 | Pegcetacoplan | Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria | — | recruiting |
Catalyst news & presentations · 1
- 2026-07-30earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $41 (0% upside) · 13 analysts
- 2024-10-16William BlairOutperform
- 2024-10-16ScotiabankSector Perform
- 2024-09-24Wells FargoEqual-Weight
- 2024-09-23BairdOutperform
- 2024-09-20MizuhoNeutral
- 2024-09-20NeedhamBuy
Competitors — Paroxysmal Nocturnal Hemoglobinuria (PNH)
- none identified
Recent news
- 2026-06-26Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout - Reuters
- 2026-06-24How Apellis Pharmaceuticals Inc. (APLS) Affects Rotational Strategy Timing - Stock Traders Daily
- 2026-05-21Apellis soars on Biogen deal as biopharma index trails the market - BioWorld News
- 2026-05-18Biogen completes acquisition of Apellis Pharmaceuticals - Ophthalmology Times Europe
- 2026-05-15Deep Track (APLS) reports 4.53M shares, a 3.55% stake - Stock Titan
- 2026-05-14Biogen Completes Acquisition of Apellis Pharmaceuticals - Biogen
- 2026-05-14Apellis Pharmaceuticals (NASDAQ:APLS): Strong Growth Stock with a Technical Breakout Setup - ChartMill
- 2026-05-14Biogen to merge Apellis (NASDAQ: APLS) after tender offer closes - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.